March 18, 2020 / 11:27 AM / 13 days ago

BRIEF-Alpine Immune Sciences’ Alpn-101 Receives FDA Orphan Drug Designations For The Prevention And Treatment Of Acute Graft Versus Host Disease

March 18 (Reuters) - Alpine Immune Sciences Inc:

* ALPINE IMMUNE SCIENCES’ ALPN-101 RECEIVES FDA ORPHAN DRUG DESIGNATIONS FOR THE PREVENTION AND TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below